Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 crawled time : 14:30 save search
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $27.0 -3.33% -3.44% 270K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
Published: 2022-03-22 (Crawled : 14:30) - biospace.com/
WINT | $5.085 -10.53% -11.77% 51K
|
Health Technology
|
| O: 5.5%
H: 1.75%
C: -8.7%
covid-19 respiratory results phase 2
COVID-19 Isn’t Done with Us Yet, Vaccine Patents and a 4th Booster
Published: 2022-03-16 (Crawled : 14:30) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
covid-19 patent covid one vaccine
COVID-19 Update: Omicron BA.2 Surges, Long COVID and Mental Health
Published: 2022-03-15 (Crawled : 14:30) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.37%
H: 0.0%
C: 0.0%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: 4.13%
H: 1.11%
C: -5.22%
covid-19 health covid
eHealth Unveils Inaugural Report on Seniors and Mental Health in the COVID-19 Era
Published: 2022-03-04 (Crawled : 14:30) - prnewswire.com
EHTH | $4.51 -0.88% -0.89% 210K
|
Finance
|
| O: -1.56%
H: 0.0%
C: 0.0%
covid-19 health covid report
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2022-03-01 (Crawled : 14:30) - biospace.com/
RDHL | $0.415 -2.99% -3.08% 190K
|
Health Technology
|
| O: 0.46%
H: 0.45%
C: -10.45%
rhb-107 covid-19 phase 2 covid positive
CUE HEALTH AND KARL-ANTHONY TOWNS TEAM UP TO DONATE $250K OF CUE'S COVID-19 TESTS TO SCHOOLS IN NEW JERSEY AND MINNESOTA
Published: 2022-02-24 (Crawled : 14:30) - prnewswire.com
HLTH | $0.1488 -0.8% -0.81% 250K
|
|
| O: -6.15%
H: 7.04%
C: 3.76%
covid-19 health covid test
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.3%
H: 1.23%
C: 0.29%
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: -0.47%
H: 5.06%
C: -4.11%
covid-19 covid report phase 3 sabizabulin
Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland
Published: 2022-02-14 (Crawled : 14:30) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: -3.44%
H: 2.07%
C: -7.82%
covid-19 covid authorization switzerland vaccine
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
Published: 2022-02-11 (Crawled : 14:30) - globenewswire.com
VAXX | $0.13 -35.0% -53.85% 4.6M
|
|
| O: 3.74%
H: 0.0%
C: 0.0%
covid-19 xin covid vaccine antibody
Cue Health to Provide Highly-Accurate, Molecular COVID-19 Tests to Johns Hopkins Medicine
Published: 2022-02-07 (Crawled : 14:30) - prnewswire.com
HLTH | $0.1488 -0.8% -0.81% 250K
|
|
| O: 0.0%
H: 6.17%
C: 2.35%
covid-19 health covid test molecular
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Published: 2022-02-07 (Crawled : 14:30) - globenewswire.com
ADMP | $0.7751 0.86% 2.6% 120K
|
Health Technology
|
| O: 3.3%
H: 3.21%
C: 2.43%
covid-19 treatment phase 2 als phase 2/3 covid enroll
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
Published: 2022-02-01 (Crawled : 14:30) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.74%
H: 0.85%
C: -1.42%
diagnostic covid-19 health als acquisition covid test cancer
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-01-31 (Crawled : 14:30) - biospace.com/
VERU | $1.325 3.92% 3.77% 1.5M
|
Health Technology
|
| O: 1.69%
H: 8.74%
C: 7.88%
covid-19 fast track designation treatment fda risk fast track respiratory covid grant syndros sabizabulin designation
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Published: 2022-01-27 (Crawled : 14:30) - biospace.com/
COCP | $1.562 -1.39% 3.9K
|
Health Technology
|
| O: 1.41%
H: 1.78%
C: -1.69%
covid-19 program drug covid antiviral pharma
Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant
Published: 2021-12-22 (Crawled : 14:30) - biospace.com/
COCP | $1.562 -1.39% 3.9K
|
Health Technology
|
| O: 8.53%
H: 1.51%
C: -4.81%
covid-19 covid sars-cov-2 in vitro
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
Published: 2021-12-21 (Crawled : 14:30) - biospace.com/
CYDY | $0.15 0.06% 420K
|
Manufacturing
|
| O: 5.0%
H: 2.86%
C: 0.0%
covid-19 fda trial covid positive pons phase 3 response
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
Published: 2021-12-20 (Crawled : 14:30) - biospace.com/
NVAX | $4.15 -0.96% -0.96% 2.4M
|
Health Technology
|
| O: 11.76%
H: 2.83%
C: -12.2%
covid-19 europe covid authorization positive vaccine
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
CAPR | $5.04 4.56% 4.37% 910K
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
covid-19 therapeutics covid vaccine
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -17.85%
H: 0.0%
C: 0.0%
covid-19 covid vaccine
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.